arimoclomol (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

Niemann–Pick disease Type C

Pending FDA approval for treatment of Niemann-Pick disease Type C

Next:

Pharmacology

Mechanism of Action

Increases the production of cell protective heat shock proteins (HSPs), but only in physiologically stressed cells, such as those impacted by disease; activates proteins that act as pharmacologic chaperones to repair cells and reduce protein misfolding and aggregation, thereby allowing the cells to process accumulated lipid

Patients with Niemann-Pick disease (NPD) type C disease are unable to transport cholesterol and lipids inside of cells, which leads to abnormal accumulation of these substances within various tissues of the body, including brain tissue

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.